



Attorney Docket No. 37991-0032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Pascal BIGEY et al.

Confirmation No.: 3543

Appl. No.:

10/506,766

Examiner: Unassigned

Filing Date:

November 12, 2004

Art Unit: 1645

Title:

DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY

COMBINATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

RELEVANCE

The documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: 4

HELLER EHRMAN LLP

1717 Rhode Island Avenue, NW

Washington, DC 20036

Telephone:

(202) 912-2142

Facsimile:

(202) 912-2020

Patricia D. Granados Attorney for Applicants

Registration No. 33,683

Customer No. 26633

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet

(use as many sheets as necessary)

of

Complete if Known				
Application Number	10/506,766			
Filing Date	November 12, 2004			
First Named Inventor	Pascal BIGEY et al.			
Group Art Unit	1645			
Examiner Name	Unassigned			
Attorney Docket Number	37991-0032			

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan Passages or Relevant
Initials *	No. ¹	Number - Kind Code ²	(if known)	MIMI-DD-1111		Figures Appear
	A01	WO 99/24583	A1	5/20/1999	McGill University	
	A02	WO 97/39135	A1	10/23/1997	Board of Regents, The Univ. of Texas System	
	A03	WO 99/01157	A1	1/14/1999	Rhone-Poulenc Rorer S.A.	
<u>.</u>						
-						
	-					
	 					

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document			Pages, Columns, Lines, Where		
Examiner Initials*	Cite No.	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	Τ ⁶	
							
	 						

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Place type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/506,766	
				Filing Date	November 12, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Pascal BIGEY et al.	
				Group Art Unit	1645	
(use as many sheets as necessary)			necessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	37991-0032	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A04	SANJOY K. BHATTACHARYA et al., "A mammalian protein with specific demethylase activity for mCpG DNA", Nature, February 18, 1999, pp. 579-583, Vol. 397	
	A05	MOSHE SZYF, "The DNA Methylation Machinery as a Therapeutic Target", Current Drug Targets, 2000, pp. 101-118, Vol. 1	
	A06	ANDREW SLACK et al., "Antisense MBD2 gene therapy inhibits tumorigenesis", The Journal of Gene Medicine", 2002, pp. 381-389, Vol. 4	
	A07	MARIE-AGNES IVANOV et al., "Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy", The Journal of Gene Medicine, 2003, pp. 893-899, Vol. 5	
	_		
			_

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.